Document is current
Any future updates will be listed below
-
Authors
Takamizawa, Shigemasa
Yazaki, Shu
Kojima, Yuki http://orcid.org/0000-0002-1558-5510
Yoshida, Hiroshi
Kitadai, Rui
Nishikawa, Tadaaki
Shimoi, Tatsunori
Sudo, Kazuki
Okuma, Hitomi Sumiyoshi
Tanioka, Maki
Noguchi, Emi
Uno, Masaya
Ishikawa, Mitsuya
Kato, Tomoyasu
Fujiwara, Yasuhiro
Yonemori, Kan
- License Information
-
More Information
Article History
Received: 18 October 2021
Accepted: 2 November 2022
First Online: 24 November 2022
Declarations
:
: This study was approved by the Institutional Review Board of the National Cancer Center (Tokyo, Japan) (No. 2014–393). The requirement to obtain informed consent was waived due to the retrospective nature of the study.
: Not applicable.
: ST, SY, YK, HY, RK, TS, KS, HO, MT, MU, MI, and TK have nothing to disclose; TN reports personal fees from Takeda Pharmaceutical Company, Eisai, AstraZeneca, and Taiho outside the submitted work; EN reports personal fees from Pfizer, Taiho, Eli Lilly, AstraZeneca, Chugai, Eisai, and Novartis outside the submitted work; YF reports personal fees from AstraZeneca, Chugai, Daiichi Sankyo, Bristol-Myers, SRL, and Santen outside the submitted work; and KY reports personal fees from Pfizer, AstraZeneca, Eisai, Takeda Pharmaceutical Company, Chugai, Ono Pharmaceutical Company, Novartis, and Daiichi Sankyo outside the submitted work.
